ClinicalTrials.gg
Active, not recruitingNCT06470022COMPARE-TAVIUpdated Aug 25, 2026

Comparison of Evolut FX Versus Sapien 3 Ultra Resilia.

An interventional study of Medtronic Evolut FX and Edwards Sapien 3 Ultra Resilia in Aortic Stenosis, sponsored by Christian Juhl Terkelsen. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Christian Juhl Terkelsen · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,370
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Aortic Valve Stenosis with a site in Denmark — 13 open to participants now, 28 under way, none of them phase 3. Aortic Valve Stenosis · Denmark.

Enrollment
6th of 40
1,370 · median 214
Started
2024
with 6 others
No phase
28 of 73
7 open now
Primary completion
2027-07
later than 18 of 27 live
Registered
66th of 73
by date

Among the 73 studies in Aortic Valve Stenosis with a site in Denmark, this one is the 6th largest by enrollment of the 40 interventional ones that give a count, is one of 7 that started in 2024, is one of 28 with no phase, reaches primary completion later than 18 of the 27 other live ones, and was the 66th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

13 of the 73 studies in Aortic Valve Stenosis with a site in Denmark are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Aortic Valve Stenosis with a site in Denmark, or all of them as a file.
02

Study summary

To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.

Read the detailed description

The purpose of the "Compare-TAVI" organization is to ensure a continuous comparison of the TAVI-valves implanted, and to monitor long-term valve performances.

Purpose of present study:

To compare outcome in patients randomized to treatment with Evolut FX versus Sapien 3 Ultra Resilia.

Hypotheses:

  1. Evolut FX is non-inferior to Edwards Sapien 3 Resilia with regard to the combined endpoint (death, stroke, moderate/severe aortic regurgitation, moderate/severe valve deterioration) between the two valves being compared.
  2. There is no difference between valves in secondary safety and efficacy endpoints (see below)
  3. There is no difference in Aortic Regurgitation fraction (ARF) and Effective Orifice Area (EOA) measured by CMR (CMR-substudy, N=166)
  4. There is no difference in EOA measured invasively during dobutamine stress (hemodynamic substudy, N=440).
  5. There is no difference in occurrence of Hypoathenuated Leaflet Thickening (HALT) measured by CT (CT-substudy, N=778).
03

Conditions studied

  • Aortic Stenosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient more than 18 years of age.
  2. Patient eligible for both Evolut FX and Edwards Sapien 3 Ultra Resilia according to a TAVI heart team conference.
  3. The center experience for each of the valves considered should be more than 15 cases a year, and the treating physician should have implanted at least 15 of each valve used in the trial.
  4. The center volume should be more than 75 cases a year.
  5. The patient has given signed .
  6. TAVI performed via the femoral artery.

Exclusion criteria

Exclusion Criteria:

None

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,370 participants (actual)

Study arms

  • Active comparator
    Medtronic Evolut FX

    TAVI procedure performed with Medtronic Evolut FX

    Device: Medtronic Evolut FX

  • Active comparator
    Edwards Sapien Ultra 3 Resilia

    TAVI procedure performed with Edwards Sapien Ultra 3 Resilia

    Device: Edwards Sapien 3 Ultra Resilia

Interventions

  • DeviceMedtronic Evolut FX

    TAVI performed with Medtronic Evolut FX

  • DeviceEdwards Sapien 3 Ultra Resilia

    TAVI performed with Edwards Sapien 3 Ultra Resilia

06

What researchers measure

Primary outcomes

  1. Mortality, stroke, moderate/major aortic regurgitation, moderate/severe THV deterioration

    The primary composite endpoint is at one-year, and a non-inferiority test is performed. See separate statistical analysis plan. Separate analyses of each component of the primary outcome will be presented, in accordance with the FDA guidelines and EMA guidelines, i.e. mortality, stroke, moderate/severe aortic regurgitation and moderate/severe THV deterioration to better understand their contribution to the primary endpoint. If non-inferiority is proven for the primary composite endpoint, a split alfa is used to test for superiority if possible (alfa=0.025) and to test secondary safety and efficacy endpoints (Total alfa=0.025 for these). The composite endpoint will be re-analyzed after 3-, 5- and 10-year as superiority analyses.

    Time frame: 1-year, 3-year, 5-year, 10-year

Secondary outcomes

  1. TAVI-related complications

    conversion to open surgery during implantation, unplanned use of cardiopulmonary support (CPS), coronary artery obstruction, ventricular septal perforation, mitral valve apparatus damage or dysfunction, cardiac tamponade / pericardial effusion resulting in pericardiocentesis, valve embolization, valve migration, need for TAVI-in-TAVI deployment, using VARC-3 criteria 10, or annulus rupture, aortic rupture/perforation, aortic dissection, or other shunts than VSD.

    Time frame: 7-days

  2. Proportion with successful implantation of the chosen valve.

    This means no need for more than 1 TAVI valve, no change to another valve than planned during the procedure because it was impossible to implant the valve planned, and no conversion to surgery or procedure-related death.

    Time frame: 7-days

  3. SMART criteria for bioprosthetic valve dysfunction through 12 months

    composed of the following components: (1) hemodynamic structural valve dysfunction, defined as aortic valve mean gradient ≥ 20 mmHg at any time up to the 12-month visit echo; (2) nonstructural valve dysfunction, defined as severe prosthesis-patient mismatch or ≥ moderate total aortic regurgitation at any time up to the 12-month visit echo; (3) clinical valve thrombosis; (4) endocarditis; or (5) aortic valve reintervention.

    Time frame: 1-year

  4. Pacemaker-implantation

    New pace-maker implantation in pacemaker-naive patients.

    Time frame: 1-year

  5. Vascular and access-related complications (exploratory only)

    Major vascular access site and access-related complications resulting in endovascular or open surgery using VARC-3 criteria

    Time frame: 30-days

  6. Bleeding and transfusion (exploratory only)

    Major bleeding resulting in drop in hgb-level ≥1.86 mmol/l and/or erythrocyte transfusion ≥ 2 units, modified from BARC type 3-5 criteria

    Time frame: 30-days

  7. Endocarditis (exploratory only)

    According to VARC-3 criteria.

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  8. Reoperation (exploratory only)

    Transcatheter Aortic Valve Intervention, Surgical Aortic Valve Intervention or Balloon Angioplasty

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  9. Moderate/severe prosthesis-patient mismatch (exploratory only)

    Effective Orifice Area (EOA)/body surface area ≤0.85 cm2/m2 if BMI\<30 kg/cm2 or \<=0.70 cm2/m2 if BMI\>=30 kg/cm2., according to VARC-3 criteria.

    Time frame: 30-day

  10. Mean gradient (exploratory only)

    Aortic mean gradient, mmHg, as evaluated by Echocardiograpy Core-laboratory.

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year

  11. Pacemaker-implantation (exploratory only)

    New pacemaker in pacemaker naive-patients.

    Time frame: 30-day prior to TAVI, 30-day, 1-year, 3-year, 5-year, 10-year

  12. Readmission for congestive heart failure (exploratory only)

    Adjudicated. Only monitored until first confirmed case.

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.

  13. AMI (exploratory only)

    Acute Myocardial Infarction. Adjudicated. Only monitored until first confirmed case.

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.

  14. Revascularization (exploratory only)

    PCI (Percutaneous coronary intervention) CABG (Coronary Artery Bypass Grafting), not scheduled before TAVI

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.

  15. Atrial fibrillation (exploratory only)

    Newly diagnosed atrial fibrillation/flutter

    Time frame: 30-day, 1-year, 3-year, 5-year, 10-year.

  16. Kidney injury (exploratory only)

    Increase in renal creatinine level more than to ≥200% (AKIN stage 2-3, VARC-3 criteria) or resulting in dialysis (AKIN stage 4) according to VARC-3 criteria.

    Time frame: 30-day

07

Study locations

1 site
08

References and documents

Publications

  • Thim T, Nissen H, Niemela M, Eftekhari A, Jalanko M, Savontaus M, Jaaskelainen P, Hensey M, Jensen RV, Norgaard BL, Frederiksen CA, Vase HO, Pedersen L, Sorensen HT, Christiansen EH, Terkelsen CJ. Design and rationale of the COMPARE-TAVI 2 trial: An all-comers head-to-head comparison of Evolut FX+ and Sapien 3 Ultra Resilia transcatheter heart valves. Am Heart J. 2026 Jul;297:107387. doi: 10.1016/j.ahj.2026.107387. Epub 2026 Feb 23. PubMed 41740661 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — We are willing to collaborate in meta-analyses based on individual data where department of epidemiology, Aarhus University Hospital will be responsible for data-analyses.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Available now. Analytic will be made available when final statistical analyses performed.

Access criteria: Contact primary investigator

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jul 2027, 35 months after the start.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's planned 35 months is below that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2024
First posted
Jun 24, 2024
StartActual
Aug 9, 2024
Primary completionEst.
Jul 14, 2027
CompletionEst.
Nov 20, 2036
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06470022
Lead sponsor
Christian Juhl Terkelsen
Collaborators
Department of Clinical Epidemiology, Aarhus University, DK-8200 Aarhus N, Denmark
Responsible party
Christian Juhl Terkelsen (Professor, MD, DmSc, PhD, Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Jun 24, 2024
Start date
Aug 9, 2024
Primary completion
Jul 14, 2027 (estimated)
Completion
Nov 20, 2036 (estimated)
Last update
Aug 25, 2026

Study contacts

christian J Terkelsen, Professor
principal investigator · Department of cardiology, Aarhus University Hospital, DK-8200 Aarhus N, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion